0001325812-14-000026.txt : 20140304
0001325812-14-000026.hdr.sgml : 20140304
20140304204927
ACCESSION NUMBER: 0001325812-14-000026
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140228
FILED AS OF DATE: 20140304
DATE AS OF CHANGE: 20140304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 7
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 857-242-3700
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 7
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Christopher Nishan Garabedian
CENTRAL INDEX KEY: 0001492604
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 14667155
MAIL ADDRESS:
STREET 1: 333 RIVER STREET
STREET 2: #303
CITY: HOBOKEN
STATE: NJ
ZIP: 07030
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2014-02-28
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001492604
Christopher Nishan Garabedian
215 FIRST STREET
CAMBRIDGE
MA
02142
1
1
0
0
President and CEO
Common Stock
28078
D
Incentive Stock Option (right to buy)
29.03
2014-02-28
4
A
0
3444
0
A
2024-02-28
Common Stock
3444
3444
D
Non-Qualified Stock Option (right to buy)
29.03
2014-02-28
4
A
0
186556
0
A
2024-02-28
Common Stock
186556
186556
D
Includes 800 shares acquired under the Sarepta Therapeutics, Inc. 2013 Employee Stock Purchase Plan on February 28, 2014.
Reflects a transfer exempt under Rule 16a-12 since the date of the Reporting Persons last ownership report.
This option is exercisable at the rate of 25% of the shares on the first anniversary of the date of grant and 1/48th of the total granted shares on each monthly anniversary thereafter, such that the option will be fully exercisable on the fourth anniversary of the date of grant.
/s/ David Tyronne Howton for Christopher Garabedian
2014-03-04